漫长等待后的新时代：伏立西尼，一种用于异柠檬酸脱氢酶（IDH）突变型胶质瘤患者的突变型IDH1和IDH2酶抑制剂。 - Suppr

Suppr

超能文献

A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.

作者信息

Silvani Antonio, Franceschi Enrico

机构信息

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.

出版信息

Tumori. 2024 Jun;110(3):160-161. doi: 10.1177/03008916231217583. Epub 2024 Jan 2.

DOI:10.1177/03008916231217583

PMID:38166539

Abstract

摘要

相似文献

A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.

Tumori. 2024 Jun;110(3):160-161. doi: 10.1177/03008916231217583. Epub 2024 Jan 2.

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.

Future Oncol. 2025 Jul;21(16):2089-2099. doi: 10.1080/14796694.2025.2511587. Epub 2025 May 27.

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Neuro Oncol. 2024 Dec 25. doi: 10.1093/neuonc/noae259.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.

Vorasidenib: First Approval.

Drugs. 2024 Oct;84(10):1325-1331. doi: 10.1007/s40265-024-02097-2. Epub 2024 Oct 8.

Single center experience of IDH inhibitors in recurrent high-grade gliomas.

J Neurooncol. 2025 Nov;175(2):837-844. doi: 10.1007/s11060-025-05183-x. Epub 2025 Aug 1.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.

Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.

Low-grade -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors.

Expert Opin Pharmacother. 2025 Jul;26(10):1163-1175. doi: 10.1080/14656566.2025.2516617. Epub 2025 Jun 6.

A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma.

Curr Mol Pharmacol. 2024 Feb 29. doi: 10.2174/0118761429290327240222061812.

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.

J Pak Med Assoc. 2024 Oct;74(10):1912-1913. doi: 10.47391/JPMA.20428.

引用本文的文献

Hydroxytyrosol and Brain Tumors: Mechanisms of Action and Therapeutic Potential.

Curr Issues Mol Biol. 2025 Aug 18;47(8):667. doi: 10.3390/cimb47080667.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.

Tumori. 2024 Jun;110(3):160-161. doi: 10.1177/03008916231217583. Epub 2024 Jan 2.

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.

Future Oncol. 2025 Jul;21(16):2089-2099. doi: 10.1080/14796694.2025.2511587. Epub 2025 May 27.

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Neuro Oncol. 2024 Dec 25. doi: 10.1093/neuonc/noae259.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.

Vorasidenib: First Approval.

Drugs. 2024 Oct;84(10):1325-1331. doi: 10.1007/s40265-024-02097-2. Epub 2024 Oct 8.

Single center experience of IDH inhibitors in recurrent high-grade gliomas.

J Neurooncol. 2025 Nov;175(2):837-844. doi: 10.1007/s11060-025-05183-x. Epub 2025 Aug 1.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.

Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.

Low-grade -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors.

Expert Opin Pharmacother. 2025 Jul;26(10):1163-1175. doi: 10.1080/14656566.2025.2516617. Epub 2025 Jun 6.

A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma.

Curr Mol Pharmacol. 2024 Feb 29. doi: 10.2174/0118761429290327240222061812.

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.

J Pak Med Assoc. 2024 Oct;74(10):1912-1913. doi: 10.47391/JPMA.20428.

引用本文的文献

Hydroxytyrosol and Brain Tumors: Mechanisms of Action and Therapeutic Potential.

Curr Issues Mol Biol. 2025 Aug 18;47(8):667. doi: 10.3390/cimb47080667.